Mito.newsMito.news
← All articlesEditorial brief · abstract-levelScore 83/100Confidence medium
biorxiv2026-07-25neurobiologytherapeutics

Why this mitochondrial dysfunction preprint matters: Elunetirom, a brain-targeted TRβ prodrug, promotes neuronal plasticity and mitochondrial biogenesis-related signaling in

This biorxiv preprint matters for mitochondria agents because it engages neurobiology, therapeutics. Dysfunction-adjacent signals: dysfunction, disease context.

Mito.news · at a glance

Signal profile (abstract-level)

neurobiology · therapeutics

Score 83/100BIORXIVmedium confidenceneurobiology
83
Importance
73
Mito signal
53
Dysfunction
75
Evidence
70
Translational

Editorial signal profile from the abstract (importance score, mito keywords, dysfunction tags, evidence density, translational cues). Not a figure reproduced from the preprint PDF.

Importance thesis

This biorxiv preprint matters for mitochondria agents because it engages neurobiology, therapeutics. Dysfunction-adjacent signals: dysfunction, disease context.

Why research bots should care

Research bots need ranked importance commentary—not raw preprint dumps—so they can update literature maps without re-reading every abstract. This Mitos brief is the decision layer.

Mitochondrial context

Topics: neurobiology, therapeutics. Signals: dysfunction, disease context. Major depressive disorder and bipolar depression are disabling illnesses associated with impaired neuroplasticity, mitochondrial dysfunction, and altered cellular bioenergetics.

Key claims

  • Major depressive disorder and bipolar depression are disabling illnesses associated with impaired neuroplasticity, mitochondrial dysfunction, and altered cellular bioenergetics.
  • Elunetirom is a brain-targeted, fatty acid amide hydrolase-sensitive prodrug of LL-340001, a potent thyroid hormone receptor activator as demonstrated in transfected cell-line and brain-slice target-engagement assays.
  • We evaluated elunetirom and LL-340001 in primary cortical and mature hippocampal neuronal cultures.
  • LL-340001 also increased nuclear PGC-1α and NRF2, the number of functional mitochondria measured by MitoTracker, and ATP content.
  • Together, these findings indicate that elunetirom and LL- 340001 engage complementary neuroplasticity and mitochondrial biogenesis-related programs in neuronal systems and support further investigation of brain-targeted thyromimetic signaling as a mechanistically differentiated approach for major depressive disorder and bipolar depression.

Methods snapshot

Elunetirom is a brain-targeted, fatty acid amide hydrolase-sensitive prodrug of LL-340001, a potent thyroid hormone receptor activator as demonstrated in transfected cell-line and brain-slice target-engagement assays.

Limitations

  • Preprint — not peer-reviewed.
  • Based on title + abstract only.
  • Heuristic editorial mode (no LLM).

Open questions

  • Does full-text design support the strongest abstract claim?
  • How does this interact with mitophagy / OXPHOS / mtDNA pathways?
  • Any contradictory preprints in the same window?

Agent takeaways

  • Index under: neurobiology, therapeutics.
  • Importance score 83/100.
  • Track claim: Major depressive disorder and bipolar depression are disabling illnesses associated with impaired neuroplasticity, mitochondrial dysfunction, and altered cellular bioenergetics.
  • Cite DOI 10.64898/2026.07.21.739927; Mitos sells commentary, not the paper license.

Source

  • Elunetirom, a brain-targeted TRβ prodrug, promotes neuronal plasticity and mitochondrial biogenesis-related signaling in primary neuronal cultures
  • DOI: 10.64898/2026.07.21.739927
  • https://www.biorxiv.org/content/10.64898/2026.07.21.739927

Mitos original importance article. x402 product is this commentary.

Free HTML is above. Bots pay for JSON at /api/v1/papers/10-64898-2026-07-21-739927. Optional wallet tester: MetaMask ($0.005).

Source preprint

Elunetirom, a brain-targeted TRβ prodrug, promotes neuronal plasticity and mitochondrial biogenesis-related signaling in primary neuronal cultures

10.64898/2026.07.21.739927

Harris JR, Baccei J, Stratton W, Stahl SM, McIntyre RS, Scanlan TS, Davar G.

Related briefs